Customized phage therapies to eradicate
harmful bacteria in chronic diseases
Ness Ziona, Israel – Aug. 6, 2020 – BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live...
Positive Phase 1 cosmetic clinical study results of BX001 in acne-prone skin reported; planned advance to Phase 2 study with readout expected in the second quarter of 2021. Initial BX002 Phase 1 clinical study readout in inflammatory bowel disease expected in the fourth quarter of 2020
BiomX Inc. announced that the Company will host a conference call and live audio webcast on Thursday, May 14, 2020, at 8:00 a.m. ET to report first quarter 2020 financial results and provide a corporate update.